Aurora Biosynthetics

What Aurora Biosynthetics does

Aurora Biosynthetics is an end-to-end RNA contract development and manufacturing organisation (CDMO) headquartered in Sydney, Australia, providing Good Manufacturing Practice (GMP) plasmid DNA, GMP messenger RNA (mRNA), lipid nanoparticle (LNP) formulation, and fill-finish services. The company operates from a single, purpose-built facility that integrates every stage of RNA therapeutic production, from plasmid manufacture through to final vialed product, materially reducing the number of vendor handoffs compared with multi-site CDMO stacks and supporting shorter timelines for clinical and commercial RNA programs.

Its core technology platform spans upstream plasmid production, in-vitro transcription for mRNA, lipid-based nanoparticle assembly for drug product, and aseptic fill-finish. Aurora is positioned around regulatory alignment with the Australian Therapeutic Goods Administration (TGA) under GMP, compatibility with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) expectations, and explicit compliance with the US BIOSECURE Act, targeting biotech sponsors and pharmaceutical companies whose RNA programs require a Western, non-China-aligned manufacturing supply chain. The company was founded by Dr. Ian Nisbet and formally launched in September 2024.

Aurora generates revenue through quote-based enterprise contracts with biotech and pharmaceutical customers. Its go-to-market is direct enterprise field sales, and its first publicly disclosed anchor customer is Create Medicines, announced in September 2024. Capital intensity is partly underwritten by a $200M+ NSW Government commitment to RNA manufacturing infrastructure, which de-risks facility build-out and positions Aurora within a broader state-backed effort to establish Sydney as a regional RNA manufacturing hub.

Name

Aurora Biosynthetics

Legal name

Aurora Biosynthetics

Website

https://aurorabiosynthetics.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Aurora Biosynthetics is a Sydney-based CDMO offering end-to-end GMP RNA manufacturing services — plasmid DNA, mRNA, LNP formulation, and fill-finish — for biotech and pharmaceutical clients globally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• GMP RNA manufacturing
• Plasmid DNA production
• LNP formulation services
• Fill-finish manufacturing
• RNA therapeutics CDMO

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. GMP Manufacturing Services: End-to-end GMP services for RNA-based products including pDNA production, RNA drug substance manufacturing, LNP formulation, and fill-finish. Revenue generated through service contracts for biotech sponsors requiring clinical supply.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Aurora Biosynthetics is an integrated GMP contract development and manufacturing organization (CDMO) providing end-to-end services for RNA-based therapeutic products. Its offerings span process and analytical development, plasmid DNA production, GMP mRNA drug substance manufacturing, lipid nanoparticle (LNP) formulation, and aseptic fill-finish—all consolidated at a single purpose-built facility in Sydney, Australia operating under one quality management system.

Product overview

Aurora Biosynthetics operates as an integrated GMP manufacturing provider offering a unified platform of services for RNA-based therapeutic development. The company's service portfolio comprises five interconnected core offerings: Process & Analytical Development (for workflow design and method validation), Plasmid DNA Production (cell banking through linearized template), GMP RNA Manufacturing (in-vitro transcription through purification), GMP Lipid Nanoparticle (LNP) Formulation (encapsulation and customized formulations), and Fill-Finish Services (aseptic filling into vials, syringes, or lyophilized formats). These services are consolidated at a single purpose-built facility in Sydney, Australia, enabling end-to-end manufacturing under one quality management system with access to Australia's 43.5% R&D Tax Incentive and CTN clinical trial pathway.

Differentiator

Problem solved

Functional benefit

Products and services

• Process & Analytical Development Expert process and analytical development for therapeutic manufacturing workflows, including initial process design through comprehensive method validation. In-house analytical capabilities cover purity, potency, stability, and compliance testing for RNA-LNP programs. Target customers are biotech sponsors developing RNA-based therapeutics requiring scalable, GMP-ready processes.
• Plasmid DNA Production GMP plasmid DNA manufacturing using single-use, closed-system technologies with phase-appropriate production from research-grade plasmids through fully compliant GMP output. Production spans cell banking through linearized template to advanced purification. Designed to support mRNA therapeutics as well as cell and gene therapy programs.
• GMP RNA Manufacturing Comprehensive GMP mRNA manufacturing including sequence optimization, in-vitro transcription, enzymatic capping, and purification within single-use, closed-system environments compliant with FDA, EMA, and TGA standards. Delivers high-yield, ultra-pure mRNA for preclinical studies, clinical trials, and commercial applications for biotech and pharmaceutical sponsors.
• GMP Lipid Nanoparticle (LNP) Formulation GMP lipid nanoparticle formulation leveraging advanced mixing technologies and precision single-use systems for encapsulation of mRNA payloads. Technology-agnostic approach enables customized formulations across a range of functional LNPs with comprehensive analytical and GMP-compliant processes for RNA and other APIs.
• Fill-Finish Services Reliable GMP fill/finish solutions featuring automated aseptic filling within advanced isolator systems guaranteeing sterility, precision, and regulatory compliance. Supports multiple product formats including vials, syringes, and lyophilized preparations, from manual fills for smaller batch sizes to automated robotic technology at larger batch sizes.

Quantifiable outcome

• 43.5% R&D Tax Incentive available for eligible development programs conducted in Australia

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Create MedicinescoreStrategic or Co-development Partner · 13 September 2024Create Medicines, leaders in RNA Immuno-oncology Therapies, has been working with Aurora since September 2024 as a trusted manufacturing partner. Aurora has been instrumental in helping drive Create Medicines' programs toward patients in need, with clinical trials ongoing and an emerging pipeline of in vivo drugs.
• New South Wales GovernmentcoreStrategic or Co-development PartnerThe NSW Government has committed over $200 million to build critical RNA manufacturing infrastructure as part of a national endeavour to build a sovereign RNA ecosystem. The Government retained Aurora to help foster, support, and enable a thriving localized biotech ecosystem. Professor Hugh Durrant-Whyte serves as Chief Scientist of NSW supporting this initiative.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Lonza: Global CDMO leader with growing mRNA and LNP capabilities, including Ibex manufacturing sites. A large-scale, multi-modal incumbent that competes with Aurora for high-value mRNA programs, particularly from big pharma.
• Catalent: Large global CDMO offering mRNA manufacturing, LNP formulation, and fill-finish across multiple sites. Broader incumbent with established pharma customers; competes with Aurora on integrated mRNA programs but at greater scale and redundancy.
• National Resilience: Hybrid CDMO and biotech manufacturer with manufacturing capabilities across modalities including mRNA and cell/gene therapies. Competes with Aurora on integrated clinical supply, with a broad service portfolio.
• Samsung Biologics: Large-scale biologics CDMO with expanding mRNA and vaccine manufacturing capabilities. Competes with Aurora for clinical and commercial mRNA programs, leveraging significantly larger capacity and established big-pharma relationships.

Direct peers

• AGC Biologics: Global CDMO providing cell and gene therapy, plasmid, and viral vector manufacturing services. Comparable to Aurora in modality breadth and clinical-stage CDMO focus, with stronger geographic footprint.
• TriLink BioTechnologies: CDMO offering GMP plasmid DNA, mRNA, and LNP formulation services, including CleanCap mRNA capping technology. Direct competitor across the same pDNA-to-mRNA-to-LNP value chain Aurora occupies.
• Recipharm: European CDMO offering biologics, fill-finish, and advanced therapy manufacturing services, including mRNA capabilities. Comparable mid-to-large CDMO competitor focused on clinical-stage supply and integrated offerings.
• Aldevron: US-based CDMO specializing in GMP plasmid DNA, mRNA, and protein manufacturing for clinical and commercial applications. Closest direct peer to Aurora's plasmid and RNA drug substance offerings, with a longer commercial track record and broader customer base.

Emerging players

• Polymun Scientific: Austrian CDMO specializing in LNP-formulated RNA and DNA products for clinical trials. Niche direct competitor to Aurora's LNP formulation and RNA manufacturing services, with similar clinical-stage focus.
• Acuitas Therapeutics: Canadian LNP technology company providing LNP formulation development and manufacturing for mRNA therapeutics. Comparable to Aurora's LNP formulation service line, with deep technology focus but narrower modality scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aurora-biosynthetics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurora Biosynthetics